Biotech Co.* (Symbol) | Pharma Co. (Country) | Product | Disclosed Funding (M) | Terms/Details (Date) |
||
Aurora Biosciences Corp. (ABSC) | Greiner Bio-One GmbH (Austria) | Microplates and other plastic consumables | ND | Aurora granted Greiner non-exclusive rights to develop, manufacture, market and distribute its 3,456-well NanoWell Assay Plate for use with its UHTSS platform, as well as other consumables; the companies will collaborate on the development of new products; agreement includes an up-front technology access fee, as well as royalties (11/28) |
||
Avigen Inc. (AVGN) | Bayer AG (Germany) | Coagulin-B gene therapy for hemophilia B | $60 | Avigen will get a $15M up-front equity investment, in addition to development and manufacturing costs, milestone payments and royalties; marketing collaboration (11/16) |
||
Carrington Laboratories Inc. (CARN) | Medline Industries Inc. | Carrington's wound and skin care products | $60 | Carrington granted Medline exclusive rights to sell and market the products; the deal is worth $50M to $60M over a five-year term, including a $12.5M consideration for royalties (11/6) |
||
Cel-Sci Corp. (AMEX:CVM) | Orient Europharma (Taiwan) | Multikine | ND | Orient gains certain exclusive marketing rights for Multikine in Taiwan, Singapore, Hong Kong and Malaysia; it will fund clinical testing in those countries; Cel-Sci will manufacture the product; the two companies will share in revenues (11/20) |
||
Cephalon Inc. (CEPH) | Abbott Laboratories Inc. | Gabitril | $100 | Abbott will transfer U.S. product rights to Gabitril to Cephalon, giving the company the right to market, sell and further develop the drug; Cephalon will pay Abbott $100M over the next four years and will make an additional payment based on the product's patent life (11/1) |
||
Cephalon Inc. (CEPH) | Choongwae Pharma Corp. (Korea) | Provigil (modafinil) | ND | Cephalon granted Choongwae rights to market, sell and distribute Provigil in the Republic of Korea (11/15) |
||
Cephalon Inc. (CEPH) | Novartis Pharma AG (Switzerland) | Provigil (modafinil) | $40 | Companies will consolidate the sales and marketing efforts of four Novartis central nervous system compounds with Cephalon's Provigil for narcolepsy in the UK; Cephalon will pay Novartis about $40M and the companies will share revenues generated (11/27) |
||
Cyanotech Corp. (CYAN) | Kyowa Engineering Co. | BioAstin | ND | Cyanotech signed an agreement with Kyowa for the distribution of BioAstin in Japan; the three-year agreement calls for an up-front payment to Cyanotech and an additional payment prior to the initiation of two clinical trials (11/1) |
||
Cytogen Corp. (CYTO) | Draxis Health Inc. (Canada) | BrachySeed implants | ND | Cytogen will market and distribute BrachySeed implants for prostate cancer in the U.S. and Draxis will supply radioactive seed to Cytogen for sale in the U.S. under the 10-year license, distribution and supply agreement (12/6) |
||
Genelabs Technologies Inc. (GNLB) | Watson Pharmaceuticals Inc. | Aslera | $55 | Watson was granted an exclusive license for North American rights to Aslera; the companies also are joining forces on the development of indications forAslera aside from systemic lupus erythematosus; Watson will pay milestone payments and fees up to $55M, as well as royalties; Watson agreed to purchase 3M shares of Genelabs for$20.5M; the agreement also provides Watson with a five-year warrant to purchase 500,000 shares of Genelabs for $6.85 per share (11/13) |
||
Generex Biotechnology Corp. (GNBT) | Solvay Fluorides Inc. | Solkane 134a pharma | ND | Generex will purchase its requirements for this propellant from Solvay, which will supply it exclusively to Generex for use with pharmaceutical products delivered to the buccal cavity (10/24) |
||
Hemosol Inc. (Canada; TSE:HML) | Dompe Farmaceutici SpA (Italy) | Hemolink | C$5 US$3.3 | Hemosol entered into a memorandum of understanding for the marketing of Hemolink in Southern and Eastern Europe; Dompe will make a C$5M investment in Hemosol common shares at C$15 per share, and it has a 16-month option to make a further equity investment of C$5M at C$22.50 per share (10/31) |
||
Orphan Medical Inc. (ORPH) | Kirin Brewery Co. Ltd. (Japan) | Busulfex (busulfan) | ND | Kirin gained exclusive rights to market and distribute Busulfex injection in Asia, including Japan, China, South Korea and Taiwan (12/13) |
||
Questcor Pharmaceuticals Inc. (AMEX:QSC) | Ahn-Gook Pharmaceuticals Inc. (South Korea) | Emitasol | ND | Ahn-Gook will market Emitasol in Korea; Questcor will receive an up-front cash payment, a milestone payment and royalties on sales (12/5) |
||
United Therapeutics Corp. (UTHR) | Antigen Pharmaceuticals Ltd. (Ireland) | UT-15 | ND | Antigen will distribute UT-15 (Uniprost) in the UK and Ireland (11/16) |
||
United Therapeutics Corp. (UTHR) | Professional Detailing Inc. | Beraprost | ND | Professional Detailing will provide pre-launch and commercialization services for beraprost in the U.S. (11/2) |
||
NOTES |
||||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. |
||||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. |
||||||
** Denotes the date the item ran in BioWorld International. |
||||||
ND = Not disclosed, reported and/or available |
||||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. |
||||||